Large international study finds diabetes drug cuts cardiovascular and kidney problems

A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes. During more than five years of follow-up, cardiovascular events like heart attacks and strokes were reduced by 12% in people taking dulaglutide compared to people taking a […]

Continue reading »

Contemporary update to PROGRESS-CTO International Registry shows successful outcomes

A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total Occlusion Intervention) International Registry was presented today as late-breaking clinical science at Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions 2018. The study includes results of Chronic Total Occlusion Percutaneous Intervention (CTO PCI) for more than 3,000 patients across 20 centers in the United […]

Continue reading »